Company profile
Annalise-Ai UK Ltd
Annalise-Ai UK Ltd is a UK company with status active founded in 2020 based in London.
Company events
Reference milestones and recent Companies House filing stream events.
Accounts due
Accounts DueNext accounts due date
Confirmation statement due
Confirmation DueNext confirmation statement due date
Mortgage Create With Deed With Charge Number Charge Creation Date
MortgageMR01 | Transaction MzUxMzE3MjI3OWFkaXF6a2N4
Published 03 Apr 2026 08:23
Confirmation statement filed
ConfirmationLast confirmation statement made up date
Accounts filed
AccountsLast accounts made up date
Change Registered Office Address Company With Date Old Address New Address
AddressAD01 | Transaction MzQzOTM2MTE4MmFkaXF6a2N4
Published 14 Oct 2024 03:26
Cessation Of A Person With Significant Control
Persons-with-significant-controlPSC07 | Transaction MzQzNzM3OTM0NWFkaXF6a2N4
Published 26 Sep 2024 12:59
Confirmation Statement With No Updates
Confirmation-statementCS01 | Transaction MzQzNzM1NTY1NmFkaXF6a2N4
Published 26 Sep 2024 10:29
Notification Of A Person With Significant Control Statement
Persons-with-significant-controlPSC08 | Transaction MzQzNzM3OTg5MWFkaXF6a2N4
Published 26 Sep 2024 01:02
Incorporated
InceptionCompany registered at Companies House
Public funding
Projects
Accelerating trustworthy AI in radiology: scalable software for clinical users to independently validate commercial products at local sites
1 Apr 2024 to 31 Mar 2025
In this collaborative proposal, the Aival Analysis Lab will be used to evaluate commercial radiology AI products on imaging data representative of a broad Scottish population. We will consider two clinical treatment pathways in line with NHS Scotland service and procurement priorities: stroke triage and urgent suspicion of lung cancer triage, assessing at...
Federated AI Monitoring Service (FAMOS)
1 Feb 2024 to 31 Jan 2025
This project aims to accelerate the integration of AI in healthcare by developing a privacy-preserving Federated AI Monitoring Service (FAMOS) on top of an existing medical AI platform. Current monitoring and evaluation costs hinder small to medium-sized enterprises (SMEs) from proving the efficacy and safety of their healthcare AI products, impeding adop...